Plain-English translation of NCT06141993 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This trial is testing whether doctors can use special blood tests to predict which men with advanced prostate cancer will respond well to hormone treatments like enzalutamide or abiraterone acetate. The study looks for tiny cancer cells that float in the bloodstream and checks them for genetic markers that might show whether the medication will work for each person's cancer.
Right now, doctors don't have a reliable way to know in advance whether a patient's cancer will respond to hormone therapy. This research could help doctors predict treatment success early on, so they can make better decisions about which medication is best for each patient.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn at your first visit, again after 12 weeks of treatment, and once more if your cancer progresses. Researchers will also review a previous tumor biopsy sample from your medical records. The study team will compare your blood test results with how well the treatment works for you, which typically takes several months to see.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States